keyword
MENU ▼
Read by QxMD icon Read
search

Etanercept

keyword
https://www.readbyqxmd.com/read/29240860/cost-per-additional-responder-associated-with-ixekizumab-and-etanercept-in-the-treatment-of-moderate-to-severe-psoriasis
#1
Steven R Feldman, Shonda A Foster, Baojin Zhu, Russel Burge, Sarah Al Sawah, Orin M Goldblum
<p>BACKGROUND: Newer psoriasis treatments can achieve greater levels of effcacy than older systemic therapies; however, current pso-riasis costs are substantial. We sought to estimate costs per additional responder associated with ixekizumab and etanercept, versus placebo, using effcacy data from phase 3 clinical trials (UNCOVER-2 and UNCOVER-3).</p> <p>METHODS: In UNCOVER-2/UNCOVER-3, patients received subcutaneous placebo, etanercept 50 mg twice weekly (BIW), or ixekizumab one 80 mg injection every 2 weeks (Q2W) after a 160-mg starting dose...
December 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/29238210/biological-therapy-utilization-switching-and-cost-among-patients-with-psoriasis-retrospective-analysis-of-administrative-databases-in-southern-italy
#2
Francesca Guerriero, Valentina Orlando, Valeria Marina Monetti, Veronica Russo, Enrica Menditto
Purpose: The aim was to describe the current use of biological therapies among patients affected by psoriasis and to analyze a drug utilization profile in naïve patients in terms of switching and treatment costs in a Local Health Unit (LHU) of Southern Italy. Methods: We conducted an observational retrospective cohort analysis using the health-related administrative databases of a LHU in Southern Italy covering a population of about one million inhabitants. All subjects with a main or secondary diagnosis of psoriasis who received at least one prescription of biological therapies between January 1, 2010 and December 31, 2014 were analyzed...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29232322/incidence-of-antidrug-antibodies-in-rheumatoid-arthritis-patients-from-argentina-treated-with-adalimumab-etanercept-or-infliximab-in-a-real-world-setting
#3
Pablo J Maid, Ricardo Xavier, Rosa M Real, Ron Pedersen, Qi Shen, Lisa Marshall, Gaston Solano, Cecilia Elena Borlenghi, Rodolfo Pardo Hidalgo
BACKGROUND: Biologic agents may induce immune responses that could impact drug action. OBJECTIVES: The aims of this study were to assess antidrug antibodies (ADAs) in patients with rheumatoid arthritis (RA) from Argentina treated with etanercept, adalimumab, or infliximab at a single visit and correlate it with efficacy outcomes. METHODS: In this subset analysis of a noninterventional, multinational, cross-sectional study (NCT01981473), adult patients with RA treated continuously for 6 to 24 months with etanercept, adalimumab, or infliximab were evaluated for ADAs and trough drug concentrations of 2 days or less prior to the next scheduled dose...
December 12, 2017: Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases
https://www.readbyqxmd.com/read/29224127/defining-and-characterizing-sustained-remission-in-patients-with-rheumatoid-arthritis
#4
Jeffrey R Curtis, Mona Trivedi, Boulos Haraoui, Paul Emery, Grace S Park, David H Collier, Girish A Aras, James Chung
The objective of this study is to characterize stability and clinical features of patients with rheumatoid arthritis (RA) in sustained remission. Combination therapy with methotrexate and tumor necrosis factor inhibitors (TNFi) has increased remission rates in RA but optimal regimens to maintain remission are unknown. We describe Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subjects with Rheumatoid Arthritis (SEAM-RA) and data from a run-in period of longitudinal observation. Patients in Simplified Disease Activity Index (SDAI) remission (score ≤ 3...
December 9, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/29220542/safety-and-efficacy-of-apremilast-through-104-weeks-in-patients-with-moderate-to-severe-psoriasis-who-continued-on-apremilast-or-switched-from-etanercept-treatment-findings-from-the-liberate-study
#5
K Reich, M Gooderham, A Bewley, L Green, J Soung, R Petric, J Marcsisin, J Cirulli, R Chen, V Piguet
BACKGROUND: Apremilast, an oral phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate to severe psoriasis. OBJECTIVE: To evaluate long-term efficacy and safety of apremilast in biologic-naive patients with moderate to severe plaque psoriasis and safety of switching from etanercept to apremilast in the phase 3b LIBERATE trial. METHODS: Two hundred fifty patients were randomized to placebo, apremilast 30 mg BID, or etanercept 50 mg QW through Week 16; thereafter, all patients continued or switched to apremilast through Week 104 (extension phase)...
December 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29215183/use-of-biological-drugs-in-patients-with-psoriasis-and-psoriatic-arthritis-in-italy-results-from-the-psong-survey
#6
Maria C Potenza, Ketty Peris, Enzo Berardesca, Luca Bianchi, Antonio Richetta, Nicoletta Bernardini, Clara De Simone, Miriam Teoli, Arianna Zangrilli, Sara D'epiro, Diego Orsini, Alessandra Narcisi, Sergio Chimenti, Antonio Costanzo
This Italian multicenter retrospective study compared the drug survival and efficacy of different anti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Drug survival rate and probability of maintaining PASI response were evaluated. The impact of dependent variables on probability of PASI 75 loss was evaluated by logistic regression...
December 7, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/29214394/serious-adverse-events-associated-with-anti-tumor-necrosis-factor-alpha-agents-in-pediatric-onset-inflammatory-bowel-disease-and-juvenile-idiopathic-arthritis-in-a-real-life-setting
#7
Serena Pastore, Samuele Naviglio, Arianna Canuto, Loredana Lepore, Stefano Martelossi, Alessandro Ventura, Andrea Taddio
OBJECTIVES: Anti-tumor necrosis factor alpha (anti-TNF-α) agents are generally well tolerated, yet they can be associated with serious adverse events (SAEs) in a minority of patients. We examined the incidence of SAEs in a pediatric referral center for chronic rheumatologic and gastroenterological inflammatory disorders. METHODS: Retrospective analysis of SAEs occurring during treatment with anti-TNF-α agents in patients with juvenile idiopathic arthritis (JIA) (n = 78)  or pediatric-onset inflammatory bowel disease (IBD) (n = 105) seen at the Institute for Maternal and Child Health IRCCS "Burlo Garofolo" in Trieste, Italy, between June 2001 and February 2016...
December 6, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/29208847/effect-of-etanercept-on-the-success-of-assisted-reproductive-technology-in-patients-with-endometrioma
#8
Göğşen Önalan, Yusuf Aytaç Tohma, Hulusi Bülent Zeyneloğlu
AIMS: To determine the effects of a tumor necrosis factor inhibitor (etanercept) on pregnancy outcomes in patients with endometrioma who were treated with assisted reproductive technology. METHODS: Sixty-eight infertile patients who had endometrioma were included in our retrospective case-control study. We administered etanercept (Enbrel, 50 mg in 1 mL intramuscularly) to 19 patients on the second day of their previous menstrual cycle. All patients were treated with assisted reproductive technology...
November 24, 2017: Gynecologic and Obstetric Investigation
https://www.readbyqxmd.com/read/29205904/dosing-down-and-then-discontinuing-biologic-therapy-in-rheumatoid-arthritis-a-review-of-the-literature
#9
REVIEW
Der-Yuan Chen, Chak Sing Lau, Bassel Elzorkany, Ping-Ning Hsu, Sonja Praprotnik, Radu Vasilescu, Lisa Marshall, Lyndon Llamado
AIM: To review the published studies that dose down and then discontinue biologic therapy in patients with rheumatoid arthritis (RA), particularly concerning the criteria for such dosing and the impact on clinical outcomes. METHODS: Published studies conducted in patients with RA that sequentially decreased the dose and then discontinued therapy were included if one or more of the following biologic disease modifying antirheumatic drugs (bDMARDs) was evaluated: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab or tocilizumab...
December 4, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29204683/wide-difference-in-biologics-usage-and-expenditure-for-the-treatment-of-patients-with-rheumatoid-arthritis-in-each-prefecture-in-japan-analyzed-using-national-database-of-health-insurance-claims-and-specific-health-checkups-of-japan
#10
Yasuyuki Kamata, Seiji Minota
To analyze the biologics usage and expenditure for the treatment of patients with rheumatoid arthritis (RA) in each prefecture throughout Japan using the national open database, the Ministry of Health, Labour and Welfare of Japan disclosed; in Oct 2016, the data of the top 30 most-frequently prescribed drugs during a 1-year period from April 2014 to March 2015 in each prefecture in Japan, along with the patients' age and sex. Seldom-used drugs were excluded. We picked up only biologics for the present study...
December 5, 2017: Rheumatology International
https://www.readbyqxmd.com/read/29200970/systematic-review-of-randomized-controlled-trials-in-the-treatment-of-dry-eye-disease-in-sjogren-syndrome
#11
REVIEW
Kendrick Co Shih, Christie Nicole Lun, Vishal Jhanji, Bernard Yu-Hor Thong, Louis Tong
Primary Sjögren's syndrome is an autoimmune disease characterized by dry eye and dry mouth. We systematically reviewed all the randomized controlled clinical trials published in the last 15 years that included ocular outcomes. We found 22 trials involving 9 topical, 10 oral, 2 intravenous and 1 subcutaneous modalities of treatment. Fluoromethalone eye drops over 8 weeks were more effective than topical cyclosporine in the treatment of dry eye symptoms and signs; similarly, indomethacin eye drops over 1 month were more efficacious than diclofenac eye drops...
2017: Journal of Inflammation
https://www.readbyqxmd.com/read/29198671/effect-of-etanercept-concentration-on-human-islet-integrity
#12
S Acreman, H Brandhorst, A Abraham, P R V Johnson, D Brandhorst
BACKGROUND: Etanercept is widely used as an antiinflammatory drug to improve engraftment after intraportal islet transplantation. In contrast to other immunosuppressive agents, very little is known about detrimental effects of etanercept on islets. The aim of this pilot study was to define the toxic range of etanercept. METHODS: Human islets isolated from 8 donors were cultured for 4-5 days at 37°C in culture medium supplemented with etanercept at concentrations from 2...
December 2017: Transplantation Proceedings
https://www.readbyqxmd.com/read/29197108/refining-a-claims-based-algorithm-to-estimate-biologic-medication-effectiveness-and-cost-per-effectively-treated-patient-with-rheumatoid-arthritis
#13
Ryan A Popp, Karen Rascati, Matthew Davis, Ujas Patel
BACKGROUND: Claims data generally lack information on clinical outcomes. However, a validated, claims-based algorithm for estimating effectiveness of biologic agents in treating rheumatoid arthritis (RA) has recently been developed and applied to various databases. OBJECTIVES: The objectives of the study were to implement a claims-based algorithm in a large nationwide database to estimate medication effectiveness and cost for patients with RA using biologic disease-modifying antirheumatic drugs (DMARDs) and to assess the effect of eliminating one criterion from the algorithm on results...
December 1, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/29190292/tnf-%C3%AE-blockade-suppresses-pericystic-inflammation-following-anthelmintic-treatment-in-porcine-neurocysticercosis
#14
Siddhartha Mahanty, Miguel A Orrego, Carla Cangalaya, M Paz Adrianzen, Gianfranco Arroyo, Juan Calcina, Armando E Gonzalez, Héctor H García, Cristina Guerra-Giraldez, Theodore E Nash
BACKGROUND: Neurocysticercosis (NCC) is an infection of the brain with the larval cyst of the tapeworm, Taenia solium. Cysticidal treatment induces parasite killing resulting in a post inflammatory response and seizures, which generally requires corticosteroid treatment to control inflammation. The nature of this response and how to best control it is unclear. We investigated the anti-inflammatory effects of pretreatment with etanercept (ETN), an anti-tumor necrosis factor agent, or dexamethasone (DEX), a high potency corticosteroid, on the post treatment inflammatory response in naturally infected pigs with neurocysticercosis after a single dose of the cysticidal drug praziquantel (PZQ)...
November 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/29189133/risk-assessment-and-monitoring-of-antibody-responses-to-biosimilars-in-chronic-inflammatory-diseases
#15
Iris Detrez, Ann Gils
BACKGROUND: The expiry of the patent of several leading biological medicinal products has led to a surge in the development of 'biosimilar' products. In contrast to generic small-molecule medicines, biosimilars are not identical to their reference medicinal products. METHODS: Full comparability in quality as well as in preclinical and clinical issues is required to register a biosimilar. Since immunogenicity is key for biological medicinal products, regulatory authorities in the European Union require antidrug antibody (ADA) responses to be evaluated and to be approached from a safety perspective...
November 29, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29185966/the-prevalence-and-clinical-effect-of-immunogenicity-of-tnf-%C3%AE-blockers-in-patients-with-axial-spondyloarthritis
#16
Gil Bornstein, Merav Lidar, Pnina Langevitz, Alexander Fardman, Ilan Ben-Zvi, Chagai Grossman
OBJECTIVES: To evaluate the prevalence of immunogenicity of TNF-α blockers in axial spondyloarthritis (SpA) patients and to assess the effect of immunogenicity on drug levels and clinical response. METHPDS: Patients with axial SpA treated with either infliximab (INF), adalimumab (ADA) or etanercept (ETN) were recruited to our observational cross-sectional study. Demographic and clinical data were collected and disease activity scores were assessed. Drug trough levels and anti-drug antibodies were measured in serum samples and collected before the next administration...
November 28, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29184553/tumor-necrosis-factor-alpha-targeting-can-protect-against-arthritis-with-low-sensitization-to-infection
#17
Nadia Belmellat, Luca Semerano, Noria Segueni, Diane Damotte, Patrice Decker, Bernhard Ryffel, Valérie Quesniaux, Marie-Christophe Boissier, Eric Assier
Tumor necrosis factor-alpha (TNF-α) blockade is an effective treatment for rheumatoid arthritis (RA) and other inflammatory diseases, but in patients, it is associated with reduced resistance to the infectious agents Mycobacterium tuberculosis and Listeria monocytogenes, among others. Our goal was to model infection and arthritis in mice and to compare etanercept, a currently used anti-TNF-α inhibitor, to an anti-TNF-α vaccine. We developed a murine surrogate of the TNF-α kinoid and produced an anti-murine TNF-α vaccine (TNFKi) composed of keyhole limpet hemocyanin conjugated to TNF-α, which resulted in anti-TNF-α antibody production in mice...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29183731/intentional-and-unintentional-medication-non-adherence-in-psoriasis-the-role-of-patients-medication-beliefs-and-habit-strength
#18
Rachael J Thorneloe, Christopher E M Griffiths, Richard Emsley, Darren M Ashcroft, Lis Cordingley
Medication non-adherence is a missed opportunity for therapeutic benefit. We assessed 'real-world' levels of self-reported non-adherence to conventional and biologic systemic therapies used for psoriasis and evaluated psychological and biomedical factors associated with non-adherence using multivariable analyses. Latent profile analysis (LPA) was used to investigate whether patients can be categorised into groups with similar medication beliefs. LPA categorises individuals with similar profiles on a set of continuous variables into discrete groups represented by a categorical latent variable...
November 25, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29180236/-economic-impact-of-etanercept-and-adalimumab-biosimilars-on-hospitals-scale-covered-by-pharmalp-ain-a-hospitals-grouping-of-orders-for-health-products
#19
B Berreur, F Guerin, B Christophe, G Limido, P Paubel
OBJECTIVES: To evaluate the economic impact of future prescriptions of etanercept and adalimumab biosimilars at the territorial scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products. METHODS: Determination of the number and status of patients (naive or in continuation of treatment) from the National Database "Datamart de Consommation Inter-Régimes" of health insurance, concerned by a dispensation in a pharmacy of etanercept or adalimumab in 2015...
November 24, 2017: Annales Pharmaceutiques Françaises
https://www.readbyqxmd.com/read/29175284/increased-risk-of-vitiligo-following-anti-tnf-therapy-a-10-year-population-based-cohort-study
#20
Jung Min Bae, Miri Kim, Han Hee Lee, Ki-Jo Kim, Hyoseung Shin, Hyun Jeong Ju, Gyong Moon Kim, Chul Jong Park, Hyun Jeong Park
Anti-tumor necrosis factor-alpha (anti-TNF) therapy is used to treat a wide range of chronic inflammatory conditions. However, there have been increasing reports of development of vitiligo and alopecia areata (AA) secondary to anti-TNF therapy. In this study, we investigated the risks of vitiligo and AA in patients with ankylosing spondylitis, Crohn's disease, or ulcerative colitis who were treated with or without anti-TNF therapy, using data from the Korean National Health Insurance Claims database from 2007 to 2016...
November 23, 2017: Journal of Investigative Dermatology
keyword
keyword
26126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"